Lenalidomide Rafarm

Lenalidomide, the active ingredient in Lenalidomide Rafarm, is an immunomodulatory drug presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with del(5q) in adult patients.

GNH USA supplies Lenalidomide Rafarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, acting on malignant plasma cells and abnormal bone‑marrow clones. - Multiple Myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and may achieve cytogenetic remission. - Maintenance Therapy after Stem Cell Transplant: prolongs disease‑free interval in eligible patients.

Lenalidomide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels causing bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: mild skin eruptions. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: profound immune suppression. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary primary malignancies: emergence of new cancers. - Pregnancy termination: teratogenic effects leading to fetal loss.

Lenalidomide requires careful monitoring and specific safety measures. - Pregnancy contraindication: teratogenic; ensure effective contraception for both sexes. - Blood count monitoring: perform regular CBC to detect neutropenia or thrombocytopenia. - Thromboembolic risk: assess need for prophylactic anticoagulation, especially in high‑risk patients. - Renal impairment: adjust dosing and monitor renal function. - Drug interaction vigilance: avoid concomitant use with strong CYP3A4 inducers or other teratogenic agents. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Thalidomide: combined teratogenic risk and overlapping toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased bleeding risk. - Live vaccines: heightened risk of infection due to immunosuppression. - Hormonal contraceptives containing estrogen: reduced efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - NSAIDs: potential additive effect on platelet inhibition. - Antihypertensives: monitor blood pressure as fluid shifts may occur. - Proton pump inhibitors: possible effect on absorption. - Herbal supplements (e.g., St. John’s wort): may alter metabolism.